Dehydroevodiamine Alleviates Doxorubicin-Induced Cardiomyocyte Injury by Regulating Neuregulin-1/ErbB Signaling
2024

Dehydroevodiamine Protects Heart Cells from Doxorubicin Damage

publication 10 minutes Evidence: moderate

Author Information

Author(s): Jie Song, Wenying Guo, Lebo Sun

Primary Institution: Ningbo Medical Center Lihuili Hospital of Ningbo University

Hypothesis

The study aims to investigate the protective effect of dehydroevodiamine (DHE) on doxorubicin-induced cardiotoxicity and its potential mechanism.

Conclusion

DHE protects cardiomyocytes against doxorubicin by regulating the NRG1/ErbB pathway.

Supporting Evidence

  • DHE enhanced cardiomyocyte viability and decreased LDH release in a concentration- and time-dependent manner.
  • DHE significantly inhibited doxorubicin-induced cardiomyocyte apoptosis, inflammation, and oxidative stress.
  • Bioinformatics analysis showed that the protective mechanism of DHE against doxorubicin-induced cardiotoxicity was related to the ErbB signaling pathway.

Takeaway

DHE is like a superhero for heart cells, helping them stay strong and healthy even when a harmful medicine called doxorubicin is used.

Methodology

Rat H9c2 cardiomyocytes were treated with doxorubicin and dehydroevodiamine, and various assays were conducted to evaluate cell viability, apoptosis, inflammation, and oxidative stress.

Limitations

The study was conducted in vitro, and further in vivo experiments are needed to confirm the findings.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/cdr/5538740

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication